ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad(Goethe University Frankfurt), Barry Bernstein(AbbVie (United States)), Sandra Lovell(AbbVie (United States)), Barbara Da Silva‐Tillmann, Roger Trinh(AbbVie (United States)), Xavier Forns(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Stefan Zeuzem(Goethe University Frankfurt), Andrew Campbell(AbbVie (United States)), Kosh Agarwal(King's College Hospital), Eric M. Yoshida(University of British Columbia), Heiner Wedemeyer(Medizinische Hochschule Hannover), Thomas Berg(University Hospital Leipzig), Christophe Hézode(Inserm), Kris V. Kowdley(Washington State University Spokane), Mitchell L. Shiffman(Bon Secours Health System), Christine A. Collins(AbbVie (United States)), Thomas Podsadecki(AbbVie (United States))
Cited by 877
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k